VEEV (Health Care Technology) Stock Valuation & Fair Value Significantly overvalued
VEEV (Health Care Technology) trades at a blended P/E of 29.1, about 52% below its historical normal valuation, with a forward growth estimate of 11.8% and a PEG of 2.46. Analysts' one-year estimates have been hit 18% of the time.
Valuation flags
- No notable valuation flags.
Frequently asked questions
Is VEEV overvalued?
At a blended P/E of 29.1 versus its historical normal P/E of 60.0, VEEV trades about 52% below its typical valuation, with a PEG of 2.46 on 11.8% forward growth. tickerseer currently rates it significantly overvalued.
What is VEEV's fair value and PEG?
VEEV trades at a blended P/E of 29.1 against a historical normal P/E of 60.0, a PEG of 2.46, and a forward growth estimate of 11.8%.
Has tickerseer's rating of VEEV changed?
tickerseer's rating has been significantly overvalued since 2026-08-21.
Industry: Health Care Technology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. Educational content, not investment advice.